We scan new podcasts and send you the top 5 insights daily.
DESTINY-Breast05 demonstrated a 53% improvement in invasive disease-free survival over T-DM1, but exhibited a 9.6% interstitial lung disease rate, including two fatal cases. Dr. Abraham noted concurrent radiation does not elevate this risk, making early symptom recognition and rapid steroid intervention critical.
Trastuzumab deruxtecan (TDXD) and datopotamab deruxtecan (Dato-DXd) share the same cytotoxic payload, yet Dato-DXd has a much lower rate of interstitial lung disease (ILD). This indicates the toxicity is driven by the antibody-antigen interaction, not the payload itself.
A practice gap exists in managing side effects of Trastuzumab-Deruxtecan (TDXD) between specialties. Breast oncologists, with more experience, are far more aggressive with prophylactic anti-emetics and frequent imaging to detect asymptomatic ILD. This proactive approach is a key lesson for lung cancer specialists and others now adopting the drug.
For urothelial cancer patients treated with trastuzumab deruxtecan (TDXD), developing symptomatic (Grade 2) interstitial lung disease or pneumonitis is a critical event. Following protocols from other cancers, this requires permanent discontinuation of the therapy. Re-challenging the patient with TDXD after a Grade 2 event is not recommended without more disease-specific safety data.
In the DESTINY LUNG-02 trial for HER2-mutant NSCLC, the lower 5.4 mg/kg dose of Trastuzumab-Deruxtecan (TDXD) yielded a 51% response rate, compared to 28% for the higher 6.4 mg/kg dose. This paradoxical outcome was driven by significantly higher toxicity, particularly interstitial lung disease (ILD), at the higher dose, which limited patients' ability to stay on treatment.
Unlike pneumonitis from immune checkpoint inhibitors, which responds quickly to steroids, pneumonitis from ADCs like trastuzumab deruxtecan is less responsive and slower to resolve. This critical difference requires a lower threshold for holding therapy and more cautious management to avoid permanent lung damage.
While oncologists feel comfortable re-challenging patients after grade 1 asymptomatic radiographic pneumonitis resolves—monitoring them closely with six-week CT scans—they refuse to restart trastuzumab deruxtecan following grade 2 ILD. Current clinical literature lacks sufficient safety evidence to justify retreating grade 2 toxicity, leading clinicians to draw a strict line against restarting therapy.
Adopting T-DXd in early-stage breast cancer requires frequent chest CT scans to monitor for potentially fatal interstitial lung disease (ILD), a practice not standard for current therapies. This presents significant new logistical challenges, including securing insurance approvals, managing patient access, and increasing the overall burden of care.
Interstitial lung disease (ILD) is a serious risk with trastuzumab deruxtecan (TDXD). Oncologists must take it extremely seriously, engaging a pulmonologist immediately at the first sign of symptoms or CT scan findings. A collaborative, multidisciplinary approach is essential for safely managing this potentially fatal toxicity.
To proactively screen for interstitial lung disease (ILD), a serious risk with trastuzumab deruxtecan (TDXD), imaging should be conducted more frequently than the typical 12-week interval. The recommended strategy is to scan patients every nine weeks, or after every three cycles, to identify asymptomatic Grade 1 ILD cases early.
In HER2-mutant non-small cell lung cancer, the DESTINY-Lung02 trial established that starting trastuzumab deruxtecan at 5.4 mg/kg instead of 6.4 mg/kg cuts interstitial lung disease rates from 32% down to 15%. Because antitumor efficacy and response rates remain equivalent between both doses, 5.4 mg/kg represents the necessary standard to minimize potentially fatal pulmonary toxicity.